Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
| Autor: | Yevgeniy Samyshkin, Apoorva Ambavane, Andreas Nikolaou, Eric M. Maiese, Cosmina Hogea, Feng Wang, Boris Gorsh, Jonathan C Tosh, Anshul Shah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry Health Policy Economics Econometrics and Finance (miscellaneous) Refractory Multiple Myeloma Time horizon Budget impact payer relapsed/refractory BCMA multiple myeloma ClinicoEconomics and Outcomes Research Systematic review Concomitant Emergency medicine Epidemiology Medicine budget impact analysis Immunomodulatory Agent business Adverse effect belamaf health care economics and organizations Original Research |
| Zdroj: | ClinicoEconomics and Outcomes Research: CEOR |
| ISSN: | 1178-6981 |
| Popis: | Anshul Shah,1 Jonathan C Tosh,2 Apoorva Ambavane,2 Andreas Nikolaou,2 Cosmina Hogea,3 Yevgeniy Samyshkin,4 Boris Gorsh,3 Eric M Maiese,5 Feng Wang3 1Modelling and Simulation, Evidera, Waltham, MA, USA; 2Modelling and Simulation, Evidera, London, UK; 3Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA; 4Value Evidence and Outcomes, GlaxoSmithKline, Brentford, UK; 5Value Evidence and Outcomes, GlaxoSmithKline, Philadelphia, PA, USACorrespondence: Anshul ShahEvidera, 500 Totten Pond Road, Suite 500, Waltham, MA, 02451, USATel +1 781 640 8941Email Anshul.shah@evidera.comPurpose: Estimate the budget impact of belantamab mafodotin (belamaf) for patients with relapsed/refractory multiple myeloma (RRMM) who have received ⥠4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.Methods: A budget impact analysis (BIA) was developed to estimate the cost difference between current (no belamaf) and projected (with belamaf) market scenarios over 3 years. Comparators were identified from a systematic literature review and included selinexor + dexamethasone or best supportive care. The number of treatment-eligible patients were estimated using an epidemiology model. Base-case analyses were conducted from a US commercial payer perspective (cost year: 2019). Model inputs included market share estimates, treatment duration, and costs of drug acquisition/administration, concomitant medications, adverse event (AE) management, treatment monitoring, and subsequent treatments based on published literature/cost databases. Budget impact, calculated as the difference in costs between current and projected scenarios over 3 years, was reported as cost per member per month (PMPM) and per member per year (PMPY). One-way sensitivity analysis assessed which key parameters most affected model outcomes. Alternative scenarios were tested (1- or 5-year time horizon; Medicare perspective; negligible cost of mental status change AE).Results: In a hypothetical commercial payer health plan with 1 million members, 33 patients were identified as treatment-eligible over 3 years. Introducing belamaf for patients with RRMM resulted in an estimated budget-neutral PMPM cost of â |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|